🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. CT-202

    Context Therapeutics

    Triple Negative Breast Cancer (TNBC)

    phase 1 small molecule active

    1 trial

  2. CTIM-76

    Context Therapeutics

    Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  3. CTX-10726

    Compass Therapeutics

    Gastroesophageal Cancer (GC)

    phase 1 small molecule active

    1 trial

  4. CTX-8371

    Compass Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  5. CUE-101

    Cue Biopharma

    Head and Neck Cancer

    phase 1 small molecule completed

    1 trial

  6. CUE-102

    Cue Biopharma

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  7. CXD101

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  8. Camrelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  9. Canagliflozin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  10. Cemiplimab

    Regeneron UK Limited

    Anaplastic Thyroid Cancer

    phase 1 mab active

    1 trial

  11. Cemiplimab

    Regeneron UK Limited

    Epithelial Ovarian Cancer

    phase 1 small molecule active

    1 trial

  12. Cemiplimab

    Regeneron UK Limited

    Hormone Receptor-positive Breast Cancer

    phase 1 small molecule completed

    1 trial

  13. Cemiplimab

    Regeneron UK Limited

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  14. Cemiplimab

    Regeneron UK Limited

    Lung Cancer

    phase 1 small molecule active

    1 trial

  15. Ceralasertib, IMFINZI 50 mg/mL concentrate for solution for infusion, INFLIXIMAB, MYCOPHENOLATE MOFETIL, AZD4773, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  16. Chemophase

    HALOZYME THERAPEUTICS, INC.

    Superficial Bladder Cancer

    phase 1 small molecule completed

    1 trial

  17. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  18. Ciforadenant

    Corvus Pharmaceuticals

    Renal Cell Cancer

    phase 1 small molecule completed

    1 trial

  19. Cisplatin

    Regeneron UK Limited

    Head and Neck Cancer

    phase 1 small molecule active

    1 trial

  20. Cisplatin

    AstraZeneca

    Inoperable Locally Advanced or Metastatic Biliary Tract Cancer

    phase 1 small molecule terminated

    1 trial

  21. Click-cleavable imaging in HER2-positive cancers (CleavHER trial).

    Disc Medicine

    HER2-positive tumors

    phase 1 other active

    1 trial

  22. Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies

    Lacuna Pharma Pty Ltd

    Patients suffering from cancer without further treatment options.

    phase 1 other active

    1 trial

  23. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech SE

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  24. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources